Greenwich LifeSciences (GLS) is a private biopharmaceutical company located in Houston, TX that is developing GP2, a novel peptide immunotherapy that reduces the recurrence rates of breast cancer following surgery (adjuvant setting). Upcoming Phase III Clinical Trial – GLS is planning to launch a Phase III clinical trial in 2019, using a similar treatment regime as the Phase IIb trial. Compelling Clinical Phase IIb Data – In a randomized single-blinded multi-centered (15 sites) Phase IIb clinical trial of 180 HLA-A02 patients of which 101 patients are Her2/neu (3+) over expressor patients, GP2 displayed outstanding efficacy. After a minimum of 4 years of follow up, there were 0% cancer recurrences in the 51 Her2/neu (3+) patients treated with GP2-GMCSF-Herceptin, when fully vaccinated with the 6 primary injection series, versus a 12% cancer recurrence rate in the 50 patient placebo arm treated with GMCSF-Herceptin (p < 0.05). The fifth year of follow up will be concluded in 2018.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):